170491 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving receptors, cell surface antigens or cell surface determinants; Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
USE OF EXTRACELLULAR VESICLES AND MICRONUCLEI OF CIRCULATING STROMAL CELLS AS PAN-CANCER BIOMARKERS FOR PREDICTING CLINICAL OUTCOMES
#2A METHOD FOR PREDICTING THE RESPONSE OF METASTASES TO IMMUNOTHERAPY IN A METASTATIC COLORECTAL CANCER PATIENT
#3METHOD OF MEASURING LEVEL OF IMMUNE SUPPRESSION
#4MARKERS OF AUTOIMMUNE DISEASES
#5TCR-INDEPENDENT MOLECULAR IDENTIFICATION OF MUTATION-RELATED AND TUMOR-SPECIFIC T CELLS
#6PERIPHERAL BLOOD BIOMARKER FOR EVALUATING ANTI-TUMOR IMMUNE EFFECT OF RADIATION THERAPY
#7COMPOSITION FOR DIAGNOSING BONE METASTASIS OF CANCER AND METHOD FOR DIAGNOSING BONE METASTASIS OF CANCER USING SAME
#8NEAR INFRA-RED LIGHT SHEET MICROSCOPY THROUGH SCATTERING TISSUES
#9ANTIGEN RECEPTOR SCREENING ASSAY
#10DETECTION OF LEUKOCYTE-DERIVED MICROVESICLES BY FLUO-SENSITIVE FLOW CYTOMETRY
#11Compositions and methods for in vitro assays of fibrin activity
#12DIAGONSIS AND TREATMENT OF AUTOIMMUNE DISEASES BY TARGETING AUTOIMMUNE-RELATED B CELLS ("ABCS")
#13TREATMENT OF NUT MIDLINE CARCINOMA
#14MONOCYTE INTEGRIN BASED MICROFLUIDIC ASSAY FOR EVALUATING CORONARY DISEASES
#15Method for assessing therapeutic effect of anti-cancer agent having anti-CD4 antibody as active ingredient
#16Methods for Predicting and Monitoring Cancer Patients' Response to Teatment by Measuring Myeloid Derived Suppressor Cells (MDSCs)
#17Use of antagonists of the interaction between HIV GP120 and α4β7 integrin
#18Compositions and methods for in vitro assays of fibrin activity
#19ANTIGEN RECEPTOR SCREENING ASSAY
#20Simultaneous Assay of Target and Target-Drug Binding
#21Use of antagonists of the interaction between HIV GP120 and α4β7 integrin
#22IN VITRO SYSTEM FOR GENERATION OF ANTIGEN-SPECIFIC IMMUNE RESPONSES
#23ISOLATION AND CHARACTERIZATION OF MUSCLE REGENERATING CELLS
#24CELLULAR BLOOD MARKERS FOR EARLY DIAGNOSIS OF ALS AND FOR ALS PROGRESSION
#25DETERMINATION OF EFFICIENT TIME(S) FOR CHEMOTHERAPY DELIVERY
#26Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension
#27METHODS OR RISK ASSESSMENT OF PML AND RELATED APPARATUS
#28Use of integrin beta subunits in the diagnosis of venous thromboembolism
#29Simultaneous Assay of Target and Target-Drug Binding
#30Non-invasive diagnostic agents and methods of diagnosing infectious disease
#31Human B1 cells and uses thereof
#32Sepsis test
#33Methods for diagnosis of myelodysplastic syndromes (MDS)
#34Assay for analysis of free drug in samples
#35METHODS AND REAGENTS FOR DETECTING SUSCEPTIBILITY TO GRAFT VERSUS HOST DISEASE OR TRANSPLANT RELATED MORTALITY
#36Non-invasive diagnostic agents and methods of diagnosing infectious disease
#37Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
#38Sepsis Test
#39COMPOSITIONS AND METHODS FOR ASSESSING DISORDERS
#40Method of analyzing lymphocytes
#41Simultaneous assay of target and target-drug binding
#42Methods for diagnosis of myelodysplastic syndromes (MDS)
#43Methods and reagents for detecting susceptibility to graft versus host disease or transplant related mortality
#44Regulation of interaction between rapl and rap1
#45Novel human beta-2 integrin alpha subunit
#46Simultaneous assay of target and target-drug binding
#47Method for indentifying integrin antagonists